Synthesis and Study of Amphotericin B Derivatives

两性霉素B衍生物的合成与研究

基本信息

项目摘要

DESCRIPTION (provided by applicant): Amphotericin has served as the gold standard for treatment of life-threatening systemic fungal infections for more than half a century, and resistance to this antibiotic remains exceptionally rare. However, amphotericin is also highly toxic, and thus the effective treatment of systemic fungal infections is all too often precluded, nt by a lack of efficacy, but by dose-limiting side effects. Because systemic fungal infections represent a major and growing threat to human health worldwide, a less toxic but equally effective amphotericin derivative stands to have a major impact. Recently, in contrast to the widely accepted channel model, we discovered that amphotericin primarily exerts its activity against yeast and human cells by simply binding ergosterol and cholesterol, respectively. Thus, rather than trying to promote the self-assembly of multimeric ion channels selectively in yeast vs. human cells, efforts toward an improved therapeutic index can now focus directly on the much simpler goal of more selectively binding ergosterol vs. cholesterol. To maximally enable the rational pursuit of this objective, we herein propose to harness the power of organic synthesis to systematically characterize the key structure-function relationships that underlie thi very rare type of small molecule-small molecule interaction. Collectively, these studies will substantially illuminate the fundamental underpinnings of AmB/sterol interactions that are central to the mechanism of action of this clinically vital antifungal agent, generate promising candidates for further development as antifungal agents with an improved therapeutic index, drive the continued development of a highly efficient and flexible building block-based platform for small molecule synthesis, as well as advance site-selective functionalizations as a powerful strategy for accessing targeted derivatives of complex natural products.
描述(由申请人提供):两性霉素已成为危及生命的全身真菌感染的黄金标准,超过半个世纪,对这种抗生素的耐药性仍然极为罕见。但是,两性霉素也具有剧毒,因此,由于缺乏疗效,但由于剂量限制的副作用而有效地治疗了全身真菌感染的有效治疗。由于系统性真菌感染代表了全世界对人类健康的主要且日益严重的威胁,因此具有重大影响的毒性较小但同样有效的两性霉素衍生物立场。最近,与广泛接受的通道模型相反,我们发现两性霉素主要通过简单地结合麦格固醇和胆固醇来对酵母和人类细胞发挥其活性。因此,与其试图在酵母和人类细胞中选择性地促进多聚体离子通道的自组装,而是为改进的治疗指数的努力直接集中在更简单的目标上,即更简单的目标是更有选择性地结合麦角固醇与胆固醇。为了最大程度地实现这一目标的合理追求,我们在这里提出的是利用有机合成的力量,以系统地表征关键结构功能关系,这些关系是基于这种非常罕见的小分子 - 小分子相互作用的类型。总的来说,这些研究将基本上阐明AMB/固醇相互作用的基本基础,这是该临床上重要的抗真菌剂的作用机制至关重要访问复杂天然产物的靶向衍生物。

项目成果

期刊论文数量(24)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
From synthesis to function via iterative assembly of N-methyliminodiacetic acid boronate building blocks.
  • DOI:
    10.1021/acs.accounts.5b00128
  • 发表时间:
    2015-08-18
  • 期刊:
  • 影响因子:
    18.3
  • 作者:
    Li J;Grillo AS;Burke MD
  • 通讯作者:
    Burke MD
Synthesis of many different types of organic small molecules using one automated process.
  • DOI:
    10.1126/science.aaa5414
  • 发表时间:
    2015-03-13
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Li J;Ballmer SG;Gillis EP;Fujii S;Schmidt MJ;Palazzolo AM;Lehmann JW;Morehouse GF;Burke MD
  • 通讯作者:
    Burke MD
Nontoxic antimicrobials that evade drug resistance.
  • DOI:
    10.1038/nchembio.1821
  • 发表时间:
    2015-07
  • 期刊:
  • 影响因子:
    14.8
  • 作者:
    Davis, Stephen A.;Vincent, Benjamin M.;Endo, Matthew M.;Whitesell, Luke;Marchillo, Karen;Andes, David R.;Lindquist, Susan;Burke, Martin D.
  • 通讯作者:
    Burke, Martin D.
Restored Physiology in Protein-Deficient Yeast by a Small Molecule Channel.
Pinene-derived iminodiacetic acid (PIDA): a powerful ligand for stereoselective synthesis and iterative cross-coupling of C(sp3) boronate building blocks.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Martin D Burke其他文献

Martin D Burke的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Martin D Burke', 18)}}的其他基金

Using a small molecule iron transporter to understand and treat FPN1 deficiencies in mice
使用小分子铁转运蛋白来了解和治疗小鼠 FPN1 缺陷
  • 批准号:
    10181021
  • 财政年份:
    2018
  • 资助金额:
    $ 44.58万
  • 项目类别:
Using a small molecule iron transporter to understand and treat FPN1 deficiencies in mice
使用小分子铁转运蛋白来了解和治疗小鼠 FPN1 缺陷
  • 批准号:
    9756457
  • 财政年份:
    2018
  • 资助金额:
    $ 44.58万
  • 项目类别:
Molecular Prosthetics and Lego Chemistry
分子修复学和乐高化学
  • 批准号:
    10552238
  • 财政年份:
    2016
  • 资助金额:
    $ 44.58万
  • 项目类别:
Synthesis and Study of Amphotericin B Derivatives
两性霉素B衍生物的合成与研究
  • 批准号:
    7929731
  • 财政年份:
    2009
  • 资助金额:
    $ 44.58万
  • 项目类别:
Synthesis of atypical carotenoids: self-preserving inhibitors of lipid peroxidati
非典型类胡萝卜素的合成:脂质过氧化物的自我保护抑制剂
  • 批准号:
    8391733
  • 财政年份:
    2009
  • 资助金额:
    $ 44.58万
  • 项目类别:
Synthesis of atypical carotenoids: self-preserving inhibitors of lipid peroxidati
非典型类胡萝卜素的合成:脂质过氧化物的自我保护抑制剂
  • 批准号:
    7993589
  • 财政年份:
    2009
  • 资助金额:
    $ 44.58万
  • 项目类别:
Synthesis of atypical carotenoids: self-preserving inhibitors of lipid peroxidati
非典型类胡萝卜素的合成:脂质过氧化物的自我保护抑制剂
  • 批准号:
    8197629
  • 财政年份:
    2009
  • 资助金额:
    $ 44.58万
  • 项目类别:
Synthesis of atypical carotenoids: self-preserving inhibitors of lipid peroxidati
非典型类胡萝卜素的合成:脂质过氧化物的自我保护抑制剂
  • 批准号:
    7767348
  • 财政年份:
    2009
  • 资助金额:
    $ 44.58万
  • 项目类别:
Synthesis and Study of Amphotericin B Derivatives
两性霉素B衍生物的合成与研究
  • 批准号:
    8505913
  • 财政年份:
    2007
  • 资助金额:
    $ 44.58万
  • 项目类别:
Synthesis and Study of Amphotericin B Derivatives
两性霉素B衍生物的合成与研究
  • 批准号:
    8078988
  • 财政年份:
    2007
  • 资助金额:
    $ 44.58万
  • 项目类别:

相似海外基金

Structure-guided development of chemical inhibitors against Kaposi’s sarcoma-associated herpesvirus (KSHV)
针对卡波西肉瘤相关疱疹病毒 (KSHV) 的化学抑制剂的结构引导开发
  • 批准号:
    9791594
  • 财政年份:
    2019
  • 资助金额:
    $ 44.58万
  • 项目类别:
Neutral lipid metabolism during Toxoplasma infection
弓形虫感染期间的中性脂质代谢
  • 批准号:
    9618357
  • 财政年份:
    2018
  • 资助金额:
    $ 44.58万
  • 项目类别:
The Tshilo Dikotla Study: Metabolic Outcomes of Children HIV/ARV-Exposed Uninfected in Botswana
Tshilo Dikotla 研究:博茨瓦纳未感染 HIV/ARV 的儿童的代谢结果
  • 批准号:
    9925218
  • 财政年份:
    2018
  • 资助金额:
    $ 44.58万
  • 项目类别:
The Tshilo Dikotla Study: Metabolic Outcomes of Children HIV/ARV-Exposed Uninfected in Botswana
Tshilo Dikotla 研究:博茨瓦纳未感染 HIV/ARV 的儿童的代谢结果
  • 批准号:
    9767955
  • 财政年份:
    2018
  • 资助金额:
    $ 44.58万
  • 项目类别:
Neutral lipid metabolism during Toxoplasma infection
弓形虫感染期间的中性脂质代谢
  • 批准号:
    9914210
  • 财政年份:
    2018
  • 资助金额:
    $ 44.58万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了